Barclays PLC Prelude Therapeutics Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Barclays PLC holds 27,165 shares of PRLD stock, worth $35,314. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,165

Previous 27,165 -0.0%

Holding current value

$35,314

Previous $57,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.07 - $6.37 $26,007 - $80,032	12,564 Added 86.05%	27,165 $57,000
Q2 2024 Aug 14, 2024	SELL	$3.32 - $5.63 $19,209 - $32,575	-5,786 Reduced 28.38%	14,601 $56,000
Q1 2024 May 15, 2024	SELL	$2.68 - $4.84 $27,172 - $49,072	-10,139 Reduced 33.21%	20,387 $97,000
Q4 2023 Feb 15, 2024	BUY	$1.69 - $4.37 $29,084 - $75,207	17,210 Added 129.24%	30,526 $131,000
Q3 2023 Nov 07, 2023	BUY	$2.74 - $4.79 $19,903 - $34,794	7,264 Added 120.03%	13,316 $42,000
Q2 2023 Aug 03, 2023	SELL	$4.45 - $8.12 $19,001 - $34,672	-4,270 Reduced 41.37%	6,052 $27,000
Q1 2023 May 04, 2023	SELL	$4.58 - $7.34 $368,699 - $590,884	-80,502 Reduced 88.64%	10,322 $59,000
Q4 2022 Feb 13, 2023	BUY	$4.61 - $8.5 $394,874 - $728,076	85,656 Added 1657.43%	90,824 $549,000
Q3 2022 Nov 03, 2022	BUY	$5.0 - $8.82 $5,540 - $9,772	1,108 Added 27.29%	5,168 $34,000
Q2 2022 Aug 12, 2022	SELL	$4.0 - $7.55 $7,268 - $13,718	-1,817 Reduced 30.92%	4,060 $21,000
Q1 2022 May 16, 2022	BUY	$6.9 - $13.22 $40,551 - $77,693	5,877 New	5,877 $40,000

Others Institutions Holding PRLD

# of Institutions

Shares Held

35.7M

Call Options Held

500

Put Options Held

300

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account